15289-s-bos

154 | Chapter 9 References 1. Versmissen J, Oosterveer DM, Yazdanpanah M et al. Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ (Clinical research ed) 2008;337:a2423. 2. Thanassoulis G, Campbell CY, Owens DS et al. Genetic associations with valvular calcification and aortic stenosis. The New England journal of medicine 2013;368:503-12. 3. Blom DJ, Hala T, Bolognese M et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. The New England journal of medicine 2014;370:1809-19. 4. Davidson MH. Emerging low-density lipoprotein therapies: Targeting PCSK9 for low-density lipoprotein reduction. J Clin Lipidology 2013;7:S11-S15. 5. Desai NR, Kohli P, Giugliano RP et al. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: An analysis from the LDL-C assessment with proprotein convertase subtilisin kexin type 9 monoclonal antibody inhibition combined with statin therapy (LAPLACE)-thrombolysis in myocardial infarction (TIMI) 57 Trial. Circulation 2013;128:962-969. 6. Raal F, Stein E, Scott R, Somaratne R, Bridges I, Wasserman SM. Reduction of LDL-C with PCSK9 inhibition in heterozygous familial hypercholesterolemia disorder (RUTHERFORD): Results from a phase 2, randomized, double-blind, placebo-controlled trial. Circulation 2012;126:2781-2782. 7. FDA Approved instructions of use of PRALUENT. 8. Amgen news release: “Amgen Announces Repatha® (Evolocumab) Significantly Reduced The Risk Of Cardiovascular Events In FOURIER Outcomes Study”. 9. Schulman KA, Balu S, Reed SD. Specialty Pharmaceuticals for Hyperlipidemia--Impact on Insurance Premiums. The New England journal of medicine 2015;373:1591-3. 10. Belcaro G, Nicolaides AN, Ramaswami G et al. Carotid and femoral ultrasound morphology screening and cardiovascular events in low risk subjects: a 10-year follow-up study (the CAFES-CAVE study(1)). Atherosclerosis 2001;156:379-87. 11. Bots ML, Hoes AW, Koudstaal PJ, Hofman A, Grobbee DE. Common carotid intima-media thickness and risk of stroke and myocardial infarction: the Rotterdam Study. Circulation 1997;96:1432-7. 12. Burke GL, Evans GW, Riley WA et al. Arterial wall thickness is associated with prevalent cardiovascular disease inmiddle-aged adults.The Atherosclerosis Risk in Communities (ARIC) Study. Stroke 1995;26:386- 91. 13. Polak JF, Szklo M, Kronmal RA et al. The value of carotid artery plaque and intima-media thickness for incident cardiovascular disease: the multi-ethnic study of atherosclerosis. Journal of the American Heart Association 2013;2:e000087. 14. Furberg CD, Adams HP, Jr., Applegate WB et al. Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group. Circulation 1994;90:1679-87. 15. de Groot E, Jukema JW, Montauban van Swijndregt AD et al. B-mode ultrasound assessment of pravastatin treatment effect on carotid and femoral artery walls and its correlations with coronary arteriographic findings: a report of the Regression Growth Evaluation Statin Study (REGRESS). J Am Coll Cardiol 1998;31:1561-7. 16. KasteleinJJ,AkdimF,StroesESetal.Simvastatinwithorwithoutezetimibeinfamilialhypercholesterolemia. The New England journal of medicine 2008;358:1431-43. 17. ten Kate GL, ten Kate GJ, van den Oord SC et al. Carotid plaque burden as a measure of subclinical coronary artery disease in patients with heterozygous familial hypercholesterolemia. The American journal of cardiology 2013;111:1305-10. 18. Chan KL, Teo K, Dumesnil JG, Ni A, Tam J, Investigators A. Effect of Lipid lowering with rosuvastatin on progression of aortic stenosis: results of the aortic stenosis progression observation: measuring effects of rosuvastatin (ASTRONOMER) trial. Circulation 2010;121:306-14. 19. Rossebo AB, Pedersen TR, Boman K et al. Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis. The New England journal of medicine 2008;359:1343-56.